AXL functions as an upstream regulator of AKT-mediated resistance to BRAF inhibitors in melanoma with wildtype PTEN [51], while AKT and Fascin regulate each other [52, 53], creating potential feedback mechanisms that may stabilize the pro-metastatic state. The gene discussed is AKT1; the disease is melanoma.